Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Rural health sign | Image credit: BJP7images - stock.adobe.com
FQHCs Show Low Engagement in Hypertension, Diabetes Trials

April 15th 2025

A new review finds federally qualified health centers (FQHCs) are underutilized in hypertension and type 2 diabetes clinical research, despite their potential to improve trial diversity.

AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com
Housing Instability Linked to Worse Type 2 Diabetes Outcomes

April 14th 2025

Diabetes concept | Image credit: Sherry Young - stock.adobe.com
GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

April 9th 2025

AJMC
The Role of Advanced Technologies in Improving Diabetes Outcomes

April 7th 2025

Diabetes - Vitalii Vodolazskyi - stock.adobe.com.jpg
More Than 250 Million Individuals Unaware They Have Diabetes

April 7th 2025

More News

Site Logo
December 22nd 2017

Medical World News®, December 2017

AJMC Staff
Key drug approvals; alcohol cancer link.
Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017
December 22nd 2017

Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017

Jaime Rosenberg
Articles on type 2 diabetes management, colon cancer screenings, and anti-rheumatic drug approvals topped the list.
Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity
December 21st 2017

Dr Todd Hobbs Discusses Identifying and Removing Barriers to Care for Obesity

Although patients and physicians both recognize the need to discuss obesity, the lack of resources, time, and expertise often prevents physicians for offering care and patients from asking for it, explained Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer.
New SGLT2 Competitor Steglatro Approved for Type 2 Diabetes
December 21st 2017

New SGLT2 Competitor Steglatro Approved for Type 2 Diabetes

Laura Joszt, MA
A new sodium-glucose co-transporter 2 medication to treat type 2 diabetes is joining the field: the FDA approved ertugliflozin (Steglatro) from Merck and Pfizer as a single therapy and in combination with Merck’s sitagliptin (Januvia), a DPP-4 inhibitor, or with metformin.
Conference Stories That Captivated AJMC® Readers in 2017
December 21st 2017

Conference Stories That Captivated AJMC® Readers in 2017

Samantha DiGrande
In 2017, The American Journal of Managed Care® (AJMC®) covered conferences on a range of topics: oncology, diabetes, managed care, and much more. however, the most-read coverage from conferences that AJMC® attended mostly focused on cardiology trial results, particularly the cardiovascular results of diabetes medications.
Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity
December 21st 2017

Dr Jay Edelberg Discusses Results of Alirocumab by Race and Ethnicity

Trial results have shown that alirocumab (Praluent) is safe and effective across patient populations, said Jay Edelberg, MD, PhD, vice president and head of Cardiovascular Development and Cardiovascular Affairs at Sanofi.
Site Logo
December 19th 2017

The CVD-Real Trial: What Can Real-World Evidence Tell Us About Primary Prevention?

Mary Caffrey
An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.
Links Between Social Isolation, Type 2 Diabetes Show Need for Friendships
December 19th 2017

Links Between Social Isolation, Type 2 Diabetes Show Need for Friendships

Mary Caffrey
A least one US payer, CareMore, has a program to combat loneliness in seniors to prevent chronic disease and other health problems.
Improved Recommendations of Deintensification in Clinical Guidelines Is Needed
December 19th 2017

Improved Recommendations of Deintensification in Clinical Guidelines Is Needed

Laura Joszt, MA
Currently, clinical guidelines offer little guidance on deintensifying care, which is critical for balancing overuse and underuse of services.
Site Logo
December 19th 2017

Amid Uproar Over CDC's 7 Words, a Question: Why Would "Evidence-Based" Cause a Stir?

Mary Caffrey
What the CEO of the American Association for the Advancement of Science thinks about the current controversy.
The Most-Read News Stories of 2017
December 18th 2017

The Most-Read News Stories of 2017

Laura Joszt, MA
The top 5 most-read news stories included clinical content, such as an FDA approval, and policy news, such as Medicare reimbursement coverage.
Site Logo
December 18th 2017

As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?

Andrew Smith
Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.
Lack of Payer Support a Barrier to Diabetes Prevention, CDC Reports
December 17th 2017

Lack of Payer Support a Barrier to Diabetes Prevention, CDC Reports

Mary Caffrey
On the plus side, a partnership with the American Medical Association appears to have contributed to a rise in provider referrals to lifestyle modification programs.
Podcast: This Week in Managed Care—CAR T Treatments and Other Health News
December 16th 2017

Podcast: This Week in Managed Care—CAR T Treatments and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
December 15th 2017

Evaluation of the Quality Blue Primary Care Program on Health Outcomes

Qian Shi, PhD, MPH Thomas J. Yan, MS Peter Lee, BS Paul Murphree, MD, MHA Xiaojing Yuan, MPH Hui Shao, PhD, MHA William H. Bestermann, MD Selina Loupe, BS Dawn Cantrell, BA David Carmouche, MD John Strapp, BA Lizheng Shi, PhD, MSPharm
Implementation of the Quality Blue Primary Care program in Louisiana was associated with a shift in primary care delivery and reductions in overall cost.
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15th 2017

What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts

AJMC Staff
Medicare is alleging laboratories improperly billed the government for improper tests; time is running out for children receiving healthcare from CHIP; the AMA extends its diabetes prevention model to Maryland and other states.
This Week in Managed Care: December 15, 2017
December 15th 2017

This Week in Managed Care: December 15, 2017

This week, the top managed care news included coverage from the 59th American Society of Hematology Annual Meeting and Exposition; recommendations on the use of diabetes drugs with cardiovascular indications; and a new study found that despite changes in insurance plans to give consumers more clout, unnecessary medical spending remains a problem.
Site Logo
December 14th 2017

Moving Pharma Contracting Into the Era of Accountability

Thomas R. Graf, MD
A chief medical officer for a major payer outlines the challenges making sure that certain high-cost therapies are directed to the patients who need them.
Site Logo
December 14th 2017

Report Highlights Increase in Premature Deaths in the United States

Laura Joszt, MA
An analysis of behaviors, community environment, policy, clinical care, and outcomes data has found a disturbing trend in mortality in the United States, with premature deaths, drug deaths, and cardiovascular deaths all increasing.
Site Logo
December 14th 2017

For Those With Diabetes and CV Risk, Personalized Care Matters

Robert A. Gabbay, MD, PhD, FACP
From the Editor in Chief
Site Logo
December 13th 2017

MGH: Centralized population health coordinators help improve care for patients with chronic disease

Site Logo
December 13th 2017

Eldrin F. Lewis, MD, MPH, on Heart Failure's Place in Diabetes Drug Trials, and the Promise of SGLT2s in Prevention

Mary Caffrey
The payment reform movement has changed the thinking about what can be done for patients with diabetes and heart failure, for the good of patients.
Site Logo
December 12th 2017

“Sprint to Zero“: A Strategy to Address High Rates of Nontraumatic Amputations in Minority Communities

Jeffrey Carr, MD, FACC, FSCAI
CMS can take steps to raise awareness, including a specific quality measure, to ensure that testing occurs prior to nontraumatic amputation.
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 12th 2017

Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval

Mary Caffrey
The cost of insulin has been a major policy issue in recent years. FDA Commissioner Scott Gottlieb, MD, said the approval of a new choice in insulin was a sign of his commitment to giving patients lower-cost options.
Site Logo
December 11th 2017

When Goals Are Not Met in Diabetes Care

A presentation at the fall live meeting of the ACO & Emerging Healthcare Delivery Coalition® focused on the clinical and economic consequences of not meeting glycemic goals in patients with type 2 diabetes.
ADA 2018 Standards Address Drugs With CV Benefits, Hold Firm on Blood Pressure
December 10th 2017

ADA 2018 Standards Address Drugs With CV Benefits, Hold Firm on Blood Pressure

Mary Caffrey
The American Diabetes Association update has recommendations that affect liraglutide, canagliflozin, and empagliflozin.
5 Approvals and Updates From the FDA This Week
December 9th 2017

5 Approvals and Updates From the FDA This Week

Jaime Rosenberg
AJMC provides a look at some of the updates coming out of the FDA this week, from new guidance on digital health oversight to multiple new drug approvals.
FDA Approves Semaglutide, Novo Nordisk's Once-Weekly GLP-1 for Type 2 Diabetes
December 5th 2017

FDA Approves Semaglutide, Novo Nordisk's Once-Weekly GLP-1 for Type 2 Diabetes

Mary Caffrey
Semaglutide, Novo Nordisk’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes (T2D), received FDA approval Tuesday, after beating its rival in a head-to-head trial and coming to the approval process with proof of cardiovascular benefits already in hand.
Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes
December 5th 2017

Dr Todd Hobbs Discusses the Advantages of Semaglutide in Type 2 Diabetes

On December 5, 2017, FDA approved Novo Nordisk’s semaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Todd Hobbs, MD, Novo Nordisk’s vice president and chief medical officer, spoke with The American Journal of Managed Care® just ahead of FDA’s action.
Sanofi Says Toujeo Met Objective in Head-to-Head Insulin Study
December 5th 2017

Sanofi Says Toujeo Met Objective in Head-to-Head Insulin Study

Mary Caffrey
Sanofi’s newest insulin met its primary objective in a large head-to-head trial that compared it with its chief competitor.
<1
...
293031323334353637
...
98>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo